Powder: -20°C for 3 years | In solvent: -80°C for 1 year
D-Leucine ((R)-Leucine) 具有抗癫痫特性,活性比L-leucine,能够有效终止癫痫发作。在体外,它能够抑制长期点位,但基底突触传递无影响。
产品描述 | D-Leucine ((R)-Leucine) potently terminates seizures even after the onset of seizure activity. D-leucine reduces long-term potentiation but had no effect on basal synaptic transmission in vitro. |
体外活性 | D-Leucine failed to compete for binding by cognate ligands in a screen of candidate neuronal receptors, potentially suggesting a novel target. D-Leucine suppressed ongoing seizures at least as effectively as diazepam even at low doses, but without sedative effects. These studies raise the possibility that D-Leucine may represent a new class of anti-seizure agents, and that D-Leucine may have a previously unknown function in eukaryotes[1]. |
别名 | D-亮氨酸, (R)-Leucine |
分子量 | 131.17 |
分子式 | C6H13NO2 |
CAS No. | 328-38-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: < 1 mg/mL
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
D-Leucine 328-38-1 Metabolism Endogenous Metabolite Leucine inhibit DLeucine D Leucine Inhibitor D-亮氨酸 (R)-Leucine inhibitor